Abstract: The present invention relates to a specific conjugate of cytotoxic drugs and prodrug forms of said conjugate, for use in treating cancer and inflammatory diseases.

Abstract: Immune responses to a targeted antigen are increased in patients for treating human disease, by administering an immunogenic composition, wherein such patients are selected from a patient population of interest.

Abstract: The present invention concerns new recombinant viral vaccines. In particular the present invention provides combination products that comprise recombinant viral vectors and specific compounds able to improve the immune response raised in vivo by said recombinant viral vectors.

Abstract: The present invention provides a novel adjuvant for nucleic acid vaccines, and in particular the present invention provides nucleic acid vaccines that comprise, or are administered in association with PPD. The present invention also provides methods to improve the therapeutic efficacy of nucleic acid vaccines.

Abstract: Polypeptides capable of binding human IL-13 and/or of binding human IL-4 in the presence of IL-4 R? can be used in medicine, in diagnosis and in screening for agonists/antagonist of IL-13/IL-4. One such polypeptide is shown in FIG. 1.

Abstract: A invention concerns a novel method for preparing a polypeptide soluble in an aqueous solvent in the absence of detergent, and polypeptides obtainable by said method. The invention also concerns the use of said polypeptides, in particular for preparing medicines or vaccines, for fighting against bacterial and viral infections or cancers.

Abstract: The invention concerns the use of a membrane fraction of gram-negative bacteria, in particular Klebsiella pnemoniae for preparing a pharmaceutical composition that is immunostimulant and/or capable of inducing an antitumoral immune response, designed in particular for treating and preventing cancers. The invention further comprises methods for preparing said membrane factions and pharmaceutical compositions containing them, in particular combined with anticancer compounds.

Abstract: The invention relates to the use of a gram-negative bacterial membrane fraction, especially Klebsiella pneumoniae, for inducing the maturation of dendritic cells.

Abstract: The invention concerns a novel construct for expressing a gene coding for a recombinant protein of interest placed under the control of the Ptrp tryptophan operon promoter in a procaryotic host cell. The invention is characterised in that the construct comprises a nucleic sequence capable of inactivating the gene coding for a TnaA tryptophanase when said nucleic sequence is introduced in said host cell. The invention also concerns vectors containing said construct and host cells transformed by said vectors. The invention further concerns methods for producing said recombinant proteins using said novel constructs.

Abstract: Polypeptides capable of binding human IL-13 and/or of binding human IL-4 in the presence of IL-4 R&agr; can be used in medicine, in diagnosis and in screening for agonists/antagonists of IL-13/IL-4. One such polypeptide is shown in FIG. 1.

Abstract: Polypeptides capable of binding human IL-13 and/or of binding human IL-4 in the presence of IL-4 R&agr; can be used in medicine, in diagnosis and in screening for agonists/antagonist of IL-13/IL-4. One such polypeptide is shown in FIG. 1.

Abstract: The invention concerns a novel method for preparing a polypeptide soluble in an aqueous solvent in the absence of detergent, and polypeptides obtainable by said method. The invention also concerns the use of said polypeptides, in particular for preparing medicines or vaccines, for fighting against bacterial and viral infections or cancers.

Abstract: Polypeptides capable of binding human IL-13 and/or of binding human IL-4 in the presence of IL-4 R.alpha. can be used in medicine, in diagnosis and in screening for agonists/antagonists of IL-13/IL-4. One such polypeptide is shown in FIG. 1.